e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review

Date: March 21, 2019
Pages: 41
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: E8E04A29FA3EN
Leaflet:

Download PDF Leaflet

e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review
e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

e-Therapeutics Plc (e-Therapeutics) is a drug discovery and development company with focus on the treatment of cancer and neurodegeneration. It has a proprietary discovery platform based on network pharmacology and chemical biology for the discovery of drugs. The company focuses on immuno-oncology to tackle drug resistance in targeted cancer therapies and anti-infectives. e-Therapeutics has development centers in Oxford and Newcastle. The company operates through one subsidiary, InRotis Technologies Limited. e-Therapeutics is headquartered in Long Hanborough, England, the UK.

e-Therapeutics Plc Key Recent Developments

Mar 05,2019 e-therapeutics: Results for the year ended 31 January 2019
Dec 11,2018 Novo Nordisk and e-therapeutics alliance to focus on type-2 diabetes
Oct 04,2018 e-therapeutics provides interim financial results for the six months ended 31 July 2018
Mar 27,2018 e-therapeutics: Full Year Results 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

e-Therapeutics Plc - Key Facts
e-Therapeutics Plc - Key Employees
e-Therapeutics Plc - Key Employee Biographies
e-Therapeutics Plc - Major Products and Services
e-Therapeutics Plc - History
e-Therapeutics Plc - Company Statement
e-Therapeutics Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
e-Therapeutics Plc - Business Description
e-Therapeutics Plc - SWOT Analysis
SWOT Analysis - Overview
e-Therapeutics Plc - Strengths
e-Therapeutics Plc - Weaknesses
e-Therapeutics Plc - Opportunities
e-Therapeutics Plc - Threats
e-Therapeutics Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
e-Therapeutics Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 05, 2019: e-therapeutics: Results for the year ended 31 January 2019
Dec 11, 2018: Novo Nordisk and e-therapeutics alliance to focus on type-2 diabetes
Oct 04, 2018: e-therapeutics provides interim financial results for the six months ended 31 July 2018
Mar 27, 2018: e-therapeutics: Full Year Results 2018

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

e-Therapeutics Plc, Key Facts
e-Therapeutics Plc, Key Employees
e-Therapeutics Plc, Key Employee Biographies
e-Therapeutics Plc, Major Products and Services
e-Therapeutics Plc, History
e-Therapeutics Plc, Other Locations
e-Therapeutics Plc, Subsidiaries
e-Therapeutics Plc, Key Competitors
e-Therapeutics Plc, Annual Ratios
e-Therapeutics Plc, Interim Ratios
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
e-Therapeutics Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

e-Therapeutics Plc, Performance Chart (2015 - 2018)
e-Therapeutics Plc, Ratio Charts
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Summit Therapeutics Plc
Sentinel Oncology Ltd
Oxford BioMedica Plc
Domainex Ltd
Alliance Pharma Plc
Skip to top


Ask Your Question

e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: